Sailong Pharmaceutical Group Co., Ltd.
SHZ: 002898.SZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nan Gui Cai
- Employees
- 483
- Headquarters
- Zhuhai, China
- IPO year
- 2017
- Market cap
- CN¥1.5B
- Website
- https://www.sailong.cn
Loading 002898…
Loading profile data…Frequently asked questions about 002898
What does Sailong Pharmaceutical Group Co., Ltd. (002898.SZ) do?
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, gaicycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib...
Where does 002898.SZ trade?
Sailong Pharmaceutical Group Co., Ltd. (002898.SZ) trades on the Shenzhen Stock Exchange.
What sector is 002898.SZ in?
Sailong Pharmaceutical Group Co., Ltd. (002898.SZ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sailong Pharmaceutical Group Co., Ltd.?
Nan Gui Cai is the chief executive officer of Sailong Pharmaceutical Group Co., Ltd. (002898.SZ).
Where is Sailong Pharmaceutical Group Co., Ltd. headquartered?
Sailong Pharmaceutical Group Co., Ltd. is headquartered in China.
Does 002898.SZ pay a dividend?
Yes — Sailong Pharmaceutical Group Co., Ltd. (002898.SZ) paid a trailing twelve-month dividend of CNY 0.02 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 002898.SZ go public?
Sailong Pharmaceutical Group Co., Ltd. (002898.SZ) completed its initial public offering in 2017.